Browse Categories

Publications by authors named "Paramjeet Singh Kapoor"

  • Page 1 of 1
Comparative assessment of the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult indian patients with osteoarthritis of the hip or knee: A 4-week, double-blind, randomized, comparative, multicenter study.
Arvind Goregaonkar K J Mathiazhagan Ravindra R Shah Paramjeet Singh Kapoor Praveen Taneja

Curr Ther Res Clin Exp

February 2009

Background: Reports of cardiovascular adverse events (AEs) associated with the use of cyclooxygenase-2 inhibitors for the treatment of osteoarthritis (OA) have prompted the quest for a better-tolerated NSAID.

Objective: The aim of this study was to compare the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult Indian patients with OA of the hip or knee.

Methods: This 4-week, double-blind, randomized, comparative, multicenter study was undertaken to compare oral lornoxicam and diclofenac in patients with OA.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Paramjeet Singh Kapoor"

  • - Paramjeet Singh Kapoor's research primarily focuses on the comparative effectiveness and tolerability of analgesic medications for treating osteoarthritis, particularly within the Indian adult population.
  • - One of his notable studies evaluated lornoxicam 8 mg BID against diclofenac 50 mg TID, aiming to identify a safer and more effective non-steroidal anti-inflammatory drug (NSAID) amidst concerns over cardiovascular risks associated with common NSAIDs.
  • - The findings from the 4-week, double-blind randomized trial provided insights into the relative effectiveness and tolerability of these two drugs, contributing valuable data to the ongoing search for safer pain management options for osteoarthritis patients.

Privacy Policy Site Map

© LitMetric 2025. All rights reserved.